Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa

Project Information

VASA

Grant agreement ID: 815643

DOI

10.3030/815643

Project closed

EC signature date 6 May 2019

Start date 1 June 2019

End date 31 March 2026

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

No data

EU contribution

€ 6 619 342,30

Coordinated by

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (1)

Burkina Faso stakeholder meeting report

Websites, patent fillings, videos etc. (2)

Project webpage
Project social media accounts

Project social media accounts established

Publications

Peer reviewed articles (4)

Temporal modulation of gene expression in a controlled Schistosoma mansoni human infection model

Author(s): Dawei Li, Chuan Jiang, Wenyu Zhu, Emma L. Houlder, Koen A. Stam, Jan Pieter R. Koopman, Marijke Langenberg, Ranmali Kavishna, Sara Torkzadeh, Björn Andersson, Josefine Persson, Aravindan Kalyanasundaram, Mumtaz Y. Balkhi, Desalegn W. Kifle, Aryandra Arya, Hyon Jin Jeon, Birkneh T. Tadesse, Sean A. Gray, Darrick Carter, Alison M. Elliott, Florian Marks, Ali M. Harandi, Meta Roestenberg, Afzal A. S
Published in: Frontiers in Immunology, Issue 16, 2025, ISSN 1664-3224
Publisher: Frontiers Media SA
DOI: 10.3389/fimmu.2025.1707749

Molecular signatures of anthroponotic cutaneous leishmaniasis in the lesions of patients infected with Leishmania tropica.

Author(s): Nasrin Masoudzadeh; Malin Östensson; Josefine Persson; Vahid Mashayekhi Goyonlo; Christopher Agbajogu; Yasaman Taslimi; Reza Erfanian Salim; Farnaz Zahedifard; Amir Mizbani; Housein Malekafzali Ardekani; Bronwyn M. Gunn; Bronwyn M. Gunn; Sima Rafati; Ali M. Harandi; Ali M. Harandi
Published in: Scientific Reports, Vol 10, Iss 1, Pp 1-15 (2020), Issue 10, 2020, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-020-72671-7

Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection study

Author(s): Koopman JPR, Houlder EL, Janse JJ, et al.
Published in: eBioMedicine, 2023, ISSN 2352-3964
Publisher: Elsevier BV
DOI: 10.1016/j.ebiom.2023.104832

Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection.

Author(s): Weidong Zhang; Weidong Zhang; Loc Le; Loc Le; Gul Ahmad; Adebayo J. Molehin; Adebayo J. Molehin; Arif J. Siddiqui; Workineh Torben; Souvik Karmakar; Juan U. Rojo; Souad Sennoune; Souad Sennoune; Samara Lazarus; Samara Lazarus; Sabiha Khatoon; Sabiha Khatoon; Jasmin Freeborn; Jasmin Freeborn; Justin Sudduth; Justin Sudduth; Ashraf F. Rezk; Ashraf F. Rezk; David Carey; Roman F. Wolf; Roman F. Wolf;
Published in: Frontiers in Immunology, 2020, ISSN 1664-3224
Publisher: Frontiers
DOI: 10.17863/cam.54650

Other (1)

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

Author(s): International Vaccine Institute
Published in: 2026
Publisher: ClinicalTrials.gov